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OBJECTIVES Cytokine mobilization of progenitor cells from bone marrow may promote myocardial
neovascularization with relief of ischemia.
BACKGROUND Patients with coronary artery disease (CAD) have low numbers of endothelial progenitor cells
compared with healthy subjects.
METHODS Granulocyte colony-stimulating factor (G-CSF), 10 g/kg/day for five days, was adminis-
tered to 16 CAD patients. Progenitor cells were measured by flow cytometry; ischemia was
assessed by exercise stress testing and by dobutamine stress cardiac magnetic resonance
imaging.
RESULTS Granulocyte colony-stimulating factor increased CD34/CD133 cells in the circulation
from 1.5  0.2 l to 52.4  10.4 l (p  0.001), similar to the response observed in 15
healthy subjects (75.1  12.6 l, p  0.173). Indices of platelet and coagulation activation
were not changed by treatment, but C-reactive protein increased from 4.5  1.3 mg/l to 8.6 
1.3 mg/l (p  0.017). Two patients experienced serious adverse events: 1) non–ST-segment
elevation myocardial infarction (MI) 8 h after the fifth G-CSF dose, and 2) MI and death 17 days
after treatment. At 1 month after treatment, there was no improvement from baseline values
(i.e., reduction) in wall motion score (from 25.7  2.1 to 28.3  1.9, p  0.196) or segments
with abnormal perfusion (7.6  1.1 to 7.7  1.1, p  0.916) and a trend towards a greater
number of ischemic segments (from 4.5  0.6 to 6.1  1.0, p  0.068). There was no
improvement in exercise duration at 1 month (p  0.37) or at 3 months (p  0.98) versus
baseline.
CONCLUSIONS Granulocyte colony-stimulating factor administration to CAD patients mobilizes cells with
endothelial progenitor potential from bone marrow, but without objective evidence of cardiac
benefit and with the potential for adverse outcomes in some patients. (J Am Coll Cardiol


















Pascular progenitor cells circulate in the bloodstream, with
he potential for cardiovascular repair following injury (1).
dentification and characterization of these cells in humans
re controversial; however, one lineage derives from a subset
See page 1649
f CD34 hematopoietic stem cells that expresses one of
he receptors for vascular endothelial growth factor (VEGF-
), with the cell surface marker CD133 further delineating
ells with endothelial potential, and specifically referred to
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005, accepted January 25, 2005.s endothelial precursor or progenitor cells (EPCs) (2–4).
ndothelial precursor cells circulate in small numbers in
ealthy individuals (0.01% of mononuclear cells), and it is
ossible that coronary artery disease (CAD) patients, who
requently have comorbidities and require multiple medica-
ions for management, have even lower numbers of EPCs in
he circulation because of impaired production within bone
arrow or reduced survival (5–7). Accordingly, stimulation
f EPC release into the circulation may be an effective
trategy for vascular repair in patients with advanced CAD
n whom conventional treatments have failed. The purpose
f our study was to test the safety and effectiveness of a
ytokine commonly used to mobilize hematopoietic stem
ells from bone marrow—granulocyte colony-stimulating
actor (G-CSF)—in patients with CAD and chronic myo-
ardial ischemia.
ETHODS
atients and study design. In accordance with primary
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G-CSF Effects in Coronary Artery Disease November 1, 2005:1643–8ardiovascular Society (CCS) class III or IV despite prior
ttempts at coronary revascularization (and considered un-
uitable for or unwilling to undergo additional procedures)
o sooner than six months before study participation, but
ith a stable pattern of angina for at least two months, and
ad reproducible myocardial ischemia by dobutamine stress
ardiac magnetic resonance imaging (MRI). Medical ther-
py for all patients included HMG-CoA reductase inhibi-
ors, reported previously to increase levels of EPCs in the
irculation (8); all medications were maintained throughout
he study. Sixteen patients (11 men and 5 women, age range
2 to 71 years) fulfilled eligibility criteria and received
-CSF (filgrastim; Amgen, Thousand Oaks, California)
0 g/kg/day for 5 days following baseline testing. This
rotocol was approved by the Scientific Review Committee
nd the Institutional Review Board of the National Heart,
ung, and Blood Institute, and informed written consent
as obtained from all participants. Fifteen healthy subjects
11 men and 4 women, age range 19 to 55 years) partici-
ating in other protocols served as a control group for
obilization of progenitor cells, receiving the same G-CSF
ose and treatment schedule as study participants.
ssays. Circulating progenitor cells were quantitated by
utomated cell counting (CellDyn 4000, Abbott Laborato-
ies, Palo Alto, California) and flow cytometric phenotyping
EPICS, Beckman Coulter, Hialeah, Florida) on EDTA-
nticoagulated peripheral blood samples. Each sample was
iluted with HBSS (Cambrex, Walkersville, Maryland) and
.1% human serum albumin to achieve a white blood cell
ount of 107 per tube, then incubated with human IVIgG
or blocking and stained with fluorochrome-conjugated
onoclonal antibodies anti-CD45-ECD (Coulter), anti-
D34-FITC (Becton Dickinson, San Jose, California), and
nti-AC133-PE (Miltenyi Biotec, Auburn, California).
total of 105 events were acquired on each of two tubes.
ells with low forward and side scatter that expressed both
D45 and CD34 were counted as CD34 cells. CD34
nd CD133 populations were expressed as number of
irculating cells per volume of peripheral blood, based on
he nucleated cell count.
Platelet factor-4 was measured by enzyme-linked immu-
osorbent assay (Diagnostica Stago, Asnieres, France) at
Abbreviations and Acronyms
CAD  coronary artery disease
CCS  Canadian Cardiovascular Society
CRP  high-sensitivity C-reactive protein
EPC  endothelial progenitor cell
FGRE  fast gradient echo
G-CSF granulocyte colony-stimulating factor
MRI  magnetic resonance imaging
TE  echo time
TR  repetition time
SSFP  steady-state free precession
VEGF  vascular endothelial growth factoraseline and within 12 h of the third, fourth, and fifth doses af G-CSF. Samples were drawn at least 2 h after the last
eparin flush into vacutainer tubes containing citrate, the-
phylline, adenosine, and dipyridamole and immediately
laced on ice. Thrombin-antithrombin levels were mea-
ured by enzyme-linked immunosorbent assay (Behring
iagnostics, San Jose, California). C-reactive protein
CRP) was measured in plasma using a high-sensitivity
0.1 mg/l), two-site chemiluminescent enzyme immunometric
ssay (Immulite 2000, DPC, Los Angeles, California).
tress testing. Demonstration of ischemia by dobutamine
tress MRI was chosen for determination of eligibility and
he primary end point of the study. Magnetic resonance
maging was performed on a 1.5-T clinical scanner (General
lectric Medical Systems, Waukesha, Wisconsin). Five
maging planes—three short-axis (basal, mid, apical) and
wo long-axis (two- and four-chamber views)—were ac-
uired at rest and at each stress stage using either a fast
radient echo (FGRE) or steady-state free precession
SSFP) technique. The imaging parameters for FGRE/
SFP were repetition time (TR) 6.2/3.6 ms, echo time (TE)
.4/1.6 ms, flip 15/45°, 28 to 36 cm field of view, slice
hickness 5/8 mm, and matrix 192  160. Following rest
maging, dobutamine was infused at 5 g/kg/min and
ncreased to 10, 20, 30, and 40 g/kg/min in 3-min
ntervals. Atropine was administered at 0.25-mg increments
maximum dose 1 mg) if the heart rate remained 100
eats/min. At peak stress, a myocardial perfusion scan was also
erformed using gadolinium 0.1 mmol/kg given intravenously
t a rate of 5 ml/s. The perfusion scan used an echo planar
maging sequence (TR 6.4 ms, TE 1.5 ms, saturation prep flip
0°, read-out flip 20°, echo train length of 4, field of view 32 to
6, matrix 128  96, and slice thickness 8 mm). Segmental
all motion analysis was based on the 16-segment model
roposed by the American Society of Echocardiography. An
schemic response was defined as a new or worsening wall
otion abnormality or a biphasic response (improvement of
aseline wall motion abnormality at low dose with worsen-
ng at high dose) in one or more segments. The composite
all motion score during dobutamine stress was calculated
y summing the score of each of 16 segments as normal 
, hypokinetic  2, akinetic  3, or dyskinetic  4.
erfusion scans were analyzed using qualitative and semi-
uantitative analysis. Perfusion scans were scored as normal
0, mild  1, moderate  2, or severe  3, and the score
or each segment was summed to give a composite perfusion
core for each study.
As a secondary end point, symptom-limited exercise
esting was conducted using the modified Bruce protocol.
tatistical analysis. The primary efficacy end point was
respecified as 2-point improvement in MRI-determined
egional left ventricular contractile pattern (i.e., 2-point
eduction in composite wall motion score) during dobut-
mine stress at one month following G-CSF treatment
ompared with baseline measurements. Because of the absence
f treatment benefit as assessed by treadmill exercise duration
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November 1, 2005:1643–8 G-CSF Effects in Coronary Artery Diseaseescribed, enrollment was stopped early after 16 patients rather
han the intended 36 and all data were analyzed. Data were
nalyzed by Student paired t test and by repeated-measures
nalysis of variance (nonparametric Mann-Whitney test for
RP), with post-hoc Student-Newman-Keuls testing when
tatistical significance was demonstrated. Data are reported as
ean  SEM.
ESULTS
s shown in Table 1, most patients reported musculoskel-
tal pain, especially in the hips, sternum, and back, which
esponded to acetaminophen in all cases. Six patients
eported anginal chest pain; four requested nitroglycerin. As
xpected, lactate dehydrogenase, alkaline phosphatase, and
ric acid values increased significantly following G-CSF
dministration; no other values on the 20-panel chemistry
anel were significantly altered by treatment.
ellular responses to G-CSF. Granulocyte colony-
timulating factor increased white blood cells nearly five-
old, of which 80% to 90% were polymorphonuclear leuko-
ytes, from baseline values at 6 to 24 h after the fifth dose of
-CSF (Table 1). CD34 cells in sampled patients in-
reased from 1.9 0.2 l at baseline to 55.7 11.1 l after
-CSF (Fig. 1); healthy control patients increased from 2.5
.3 l to 84.3  13.3 l (p  0.118, p  0.108, respectively,
s. sampled patients). CD34/CD133 cells in patients
ncreased from 1.5 0.2 l at baseline to 52.4 10.4 l after
-CSF; healthy controls increased from 1.9  0.3 to 75.1 
2.6 l (p  0.123 and p  0.173, respectively, vs. patients).
ariability in CD34 and in CD34/CD133 mobiliza-
ion responses were apparent in our study participants as
ell as in healthy controls. One week later, CD34 and
D34/CD133 cells in blood were not significantly
ifferent from baseline values. Indices of platelet activation
nd coagulation activation were not changed by treatment,
able 1. Symptom Responses to G-CSF and Changes in
elected Laboratory Values
Baseline Day 6 Day 14
ymptoms, no. of subjects (%)
Musculoskeletal pain 0 15 (94) 0
Chest pain 0 6 (34) 0
Nitroglycerin use 0 4 (25) 0
Headache 0 3 (19) 0
aboratory values
White cell count (103/l) 6.5  0.5 39.1  2.5 5.4  0.3
Hemoglobin (g/dl) 13.4  0.5 13.4  0.4 12.9  0.4
Platelets (103/l) 218  16 206  13 233  17
Fasting glucose (mg/dl) 137  13 149  16 136  13
Alanine aminotransferase (U/l) 31  5 36  6 33  4
Lactate dehydrogenase (U/l) 147  6 351  19* 152  6
Alkaline phosphatase (U/l) 70  5 181  8* 90  6
Uric acid (mg/dl) 5.8  0.3 7.7  0.5* 5.6  0.3
-CSF treatment initiated after baseline values; Day 6  6 to 24-h after fifth and
nal dose of G-CSF 10 g/kg/day. Data are mean  SEM; *p  0.001 versus
aseline values.
G-CSF  granulocyte colony-stimulating factor.ut CRP levels increased from 4.5  1.3 mg/l to 8.6  1.3 sg/l (p  0.017) at 6 to 24 h following the fifth dose of
-CSF (Fig. 2).
-CSF and inducible ischemia. At one month after
reatment, 12 of 15 evaluable patients reported improve-
ent in symptoms (1 CCS functional class). Cardiac
RI showed no change in resting left ventricular ejection
raction as a result of treatment (Table 2). Dobutamine
nfusion provoked chest pain in all patients at baseline and
t the one-month after-treatment study at identical average
eak doses and with similar systolic blood pressure-heart
ate products. There was a trend toward a greater number of
schemic left ventricular wall segments at one month post-
reatment compared with baseline segmental responses to
obutamine, and there was no improvement in the com-
osite wall motion score, in the number of abnormally
erfused segments, or in the composite perfusion score
uring dobutamine stress as a result of G-CSF treatment.
aving observed a 2.6  1.9-point increase in the compos-
te wall motion score with 15 subjects, the set of plausible
alues for the true but unknown change in wall motion score
s given by the interval (1.5, 6.7) with probability 0.95
95% confidence). Hence, we have excluded a 2-point
ecrease (i.e., improvement consistent with reduced isch-
mia) in the wall motion score with a probability 0.95.
Treadmill exercise testing during all time points of the
igure 1. Hematopoietic progenitor cells normalized to the total mono-
uclear cell count at baseline and within 24 h of the fifth dose of
ranulocyte colony-stimulating factor (G-CSF) 10 g/kg/day in 16 coro-
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G-CSF Effects in Coronary Artery Disease November 1, 2005:1643–8mic ST-segment responses were difficult to assess because
f resting electrocardiogram (ECG) abnormalities in most
atients. There was no improvement, however, in treadmill
xercise duration (modified Bruce protocol) or systolic blood
ressure-heart rate product at 1 month, and in 12 patients at
months, compared with baseline measurements (Fig. 3).
erious adverse events. Two serious adverse events were
ncountered during our study. The first was a 52-year-old
dult-onset diabetic man with a history of two myocardial
igure 2. Plasma levels of platelet factor-4 (PF4, top panel), thrombin-
ntithrombin complexes (T-AT, middle panel), and C-reactive protein
CRP, bottom panel) at baseline and at selected days during and following
-CSF administration to 16 CAD patients. There were no differences
etween PF4 and T-AT values by analysis of variance (p  0.407 and p 
.731, respectively). A nonparametric statistic was used for CRP compar-
sons. Data is mean  SEM. Abbreviations as in Figure 1.
Table 2. Cardiac MRI Hemodynamics in 15 E
Following G-CSF Treatment
Resting left ventricular ejection fraction (%)
Peak dobutamine dose (g/kg/min)
Peak pressure-rate product (103)
Ischemic segments (n)
Wall motion score
Segments with abnormal perfusion (n)
Perfusion scoreData are mean  SEM.
G-CSF  granulocyte colony-stimulating factor; MRI  magnnfarctions and CCS functional class III angina despite
revious percutaneous coronary intervention. Cardiac MRI
howed resting anteroseptal and inferior hypokinesis of the
eft ventricle with an ejection fraction of 40%. With dobut-
mine infusion, new or worsening hypokinesis was noted in
he lateral, mid-septum, and mid-inferior walls. Eight hours
fter the fifth dose of G-CSF, he complained of severe chest
ain with nausea and diaphoresis. Electrocardiogram
howed new ST-segment depression in leads I and aVL and
ild ST-segment elevation with T-wave inversion in III,
able Patients at Baseline and at One Month
aseline Post G-CSF p Value
5  2.6 51.2  3.1 0.812
0  2.2 31.5  1.8 1.00
3  1.0 20.1  0.7 0.951
5  0.6 6.1  1.0 0.068
7  2.1 28.3  1.9 0.196
6  1.1 7.7  1.1 0.916
9  1.8 12.1  1.8 0.923
igure 3. Treadmill exercise duration (top panel) and systolic blood
ressure-heart rate (pressure-rate) product (bottom panel) using the
odified Bruce protocol for coronary artery disease patients treated with
-CSF. Mean values are identified by the bar at each time point. There
ere no differences in values among the time points of exercise testing by
nalysis of variance (p  0.479 and p  0.220, respectively). Abbreviations
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November 1, 2005:1643–8 G-CSF Effects in Coronary Artery DiseaseVF. White blood cell count was 32.7  103/l; CRP was
.5 mg/l. Troponin I peaked at 4.2 ng/ml (upper limit of
ormal 2.0 ng/ml) and creatine kinase-MB fraction peaked
t 7.1 g/l (upper limit of normal 5.0 g/l). There were no
ew wall motion abnormalities by echocardiography. The
atient was treated with enoxaparin and nitroglycerin paste;
o further chest pain was reported, and ECG changes
esolved over the next two days. Dobutamine stress cardiac
RI at one month after treatment showed similar findings
s his pretreatment study.
The second event was experienced by a 69-year-old man
ith CCS functional class IV angina and a history of
yocardial infarction, 16 percutaneous coronary interven-
ions, 2 coronary bypass operations, transmyocardial laser
evascularization, and 2 courses of enhanced external coun-
erpulsation. Cardiac MRI showed resting inferior, poste-
ior, and lateral wall motion abnormalities with an ejection
raction of 48%. New mid-posterior and apical hypokinesis
as observed with dobutamine infusion. The patient expe-
ienced three episodes of angina during the treatment period
ithout changes in his ECG. White blood cell count was
6.3  103/l and CRP was 13.4 mg/l after G-CSF. The
atient was discharged from the Clinical Center but admit-
ed to his local hospital two weeks later because of severe
hest pain, initially with negative markers for infarction.
hree days into that admission, he experienced recurrent
evere chest pain with positive markers for infarction and
eveloped electrical-mechanical dissociation followed by
systole and death. The family declined a postmortem
xamination.
ISCUSSION
e show in this study of patients with advanced CAD and
ecurrent ischemia that G-CSF, a cytokine commonly used
o mobilize hematopoietic stem cells in healthy subjects for
ransplant purposes, increases circulating CD34 and
D34/CD133 cells. Peak CD34 and CD34/
D133 responses were approximately 80% of the average
esponses measured in our healthy control population.
e have recently reported that G-CSF enhances EPC
olony-forming ability and increases chemokine receptor
xpression that is important for progenitor cell homing and
ngraftment (9). Although investigators using the hind-
imb ischemia model and the carotid injury model and a
mall clinical trial had suggested favorable effects of a
ytokine mobilization approach (10–12), no objective ben-
fit of progenitor cell mobilization was observed in our
tudy. In this regard, our study had sufficient power to
xclude a 2-point decrease (i.e., improvement consistent
ith reduced ischemia) in the MRI-determined wall motion
core with a probability 0.95. Further, we saw no im-
rovement in treadmill exercise at one and three months
ollowing treatment. Recent animal data suggest that aug-
entation of vascular progenitor cells in the circulation failo revascularize ischemic myocardium unless accompaniedy enhanced expression of homing ligands VEGF-2 and
DF-1, respectively (13,14).
Granulocyte colony-stimulating factor-induced increases
n CRP, previously reported in healthy subjects (15), may
ave contributed to two serious adverse events in our study.
poradic cases of myocardial infarction have also been
eported in cancer patients and in healthy subjects receiving
-CSF (16–21). In vitro experiments have shown that
ro-inflammatory effects of CRP (22,23) might provoke
laque destabilization and rupture in some CAD patients.
e are aware of one other study in which CRP levels were
easured in CAD patients following G-CSF administra-
ion. Kang et al. (24) reported that G-CSF did not elevate
evels of CRP in their patients, but that may have resulted
rom inclusion of patients with recent MI, in whom marked
ncreases in CRP as a result of myonecrosis might have
asked any G-CSF-related effects on CRP levels. In this
tudy, as well as that of Seiler et al. (12), in which
ranulocyte macrophage-CSF was administered to CAD
atients, no acute adverse effects of cytokine administration
ere reported.
Our findings establish that G-CSF administration to
AD patients mobilizes CD34/CD133 progenitor cells
nto the circulation, albeit to levels somewhat less than in
ealthy subjects. We found no objective evidence of cardiac
enefit, however, which may indicate that too few cells with
eovascularization potential localize to ischemic tissue for
easurable efficacy. An alternative explanation is that the
obilized bone marrow derived cells are functionally im-
aired with a reduced neovascularization capacity (25).
owever, this approach may still have clinical utility for the
urpose of leukapheresis with administration of selected or
odified cells directly into myocardium. Significant in-
reases in inflammatory cells and CRP, however, may
ontribute to adverse outcomes during treatment in some
atients.
eprint requests and correspondence: Dr. Richard O. Cannon
II, National Institutes of Health, Building 10, Room 7B15, 10
enter Drive, MSC 1650, Bethesda, Maryland 20892-1650.
-mail: cannonr@nih.gov; or Dr. Jonathan M. Hill, King’s Col-
ege London, Department of Cardiology, Bessemer Road, London
E5 9PJ, United Kingdom. E-mail: Jonathan.Hill@kcl.ac.uk.
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